Use of aprotinin in patients undergoing deep hypothermic circulatory arrest: a review.
Hemostatic derangements continue to be a major clinical challenge during thoracic aortic surgery using deep hypothermic circulatory arrest despite advances in surgical and pharmacologic therapy. Aprotinin, a broad-based, nonspecific serine protease inhibitor has been advocated for prophylactic use in cardiac surgery to decrease perioperative blood loss and blood transfusions. Its efficacy has been documented in several studies throughout the United States and Europe. Currently, aprotinin is advocated for use in patients undergoing cardiopulmonary bypass in the course of coronary artery bypass graft surgery. A review of current studies is provided that examines aprotinin usage under deep hypothermic circulatory arrest.
Huffman-Egger
Suzanne
S
University of Kansas Hospital, Kansas City, Kansas 66160, USA.
D007611:Aprotinin / Q000494:pharmacology* / Q000627:therapeutic use; D016063:Blood Loss, Surgical / Q000517:prevention & control*; D002315:Cardiopulmonary Bypass / Q000009:adverse effects / Q000379:methods*; D006324:Heart Arrest, Induced / Q000379:methods*; D006801:Humans; D007036:Hypothermia, Induced / Q000009:adverse effects / Q000379:methods*; D019990:Perioperative Care; D015842:Serine Proteinase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use
D015842:Serine Proteinase Inhibitors; D007611:Aprotinin